Plain-English translation of NCT06491082 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research follows cancer patients who are receiving platinum and taxane-based chemotherapy to see if these drugs damage nerves in the hands and feet. Researchers will perform nerve tests, measure certain vitamins and proteins in your blood, and analyze genes related to cell damage. The goal is to understand who is most likely to develop nerve damage and why.
Nerve damage is a common side effect of certain cancer chemotherapy drugs, but we don't fully understand why some patients develop it more severely than others. This study aims to identify early warning signs and biological factors that might predict who is at risk, which could help doctors prevent or manage this painful complication better in the future.
You will have nerve function tests and blood work done before you start chemotherapy and again after your 4th cycle of treatment. The nerve tests include a physical neurological exam and a test that measures how well your nerves conduct electrical signals. You will also have a small blood sample taken (about 5 milliliters) to measure vitamins, proteins, and genes related to cell damage. All testing is non-invasive and will help researchers understand how the medication affects your nerves over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
India
Sponsor
Swami Rama Himalayan University
Enrollment target
~124 participants
Started
November 2022
Primary completion
August 2024
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.